AU5713000A - Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same - Google Patents

Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same

Info

Publication number
AU5713000A
AU5713000A AU57130/00A AU5713000A AU5713000A AU 5713000 A AU5713000 A AU 5713000A AU 57130/00 A AU57130/00 A AU 57130/00A AU 5713000 A AU5713000 A AU 5713000A AU 5713000 A AU5713000 A AU 5713000A
Authority
AU
Australia
Prior art keywords
medicine
same
matrix metalloproteinases
effective composition
procyanidin oligomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57130/00A
Inventor
Ho-Jeong Ahn
Hye-Sung Cho
Seung-Young Jeoung
Jung-Hun Kim
Moon-Moo Kim
Sang-Nyun Kim
Hak-Mo Lee
Hyoung-Kook Park
Sang-Ki Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG H&H Co Ltd
Original Assignee
LG Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Chemical Co Ltd filed Critical LG Chemical Co Ltd
Publication of AU5713000A publication Critical patent/AU5713000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU57130/00A 1999-07-16 2000-07-14 Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same Abandoned AU5713000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-1999-0028877A KR100509119B1 (en) 1999-07-16 1999-07-16 Medicine comprising procyanidine as an effective agent
KR9928877 1999-07-16
PCT/KR2000/000769 WO2001005397A1 (en) 1999-07-16 2000-07-14 Procyanidin oligomers inhibiting matrix metalloproteinases and medicine having effective composition of the same

Publications (1)

Publication Number Publication Date
AU5713000A true AU5713000A (en) 2001-02-05

Family

ID=19602329

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57130/00A Abandoned AU5713000A (en) 1999-07-16 2000-07-14 Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same

Country Status (9)

Country Link
EP (1) EP1196162A4 (en)
JP (1) JP2003504402A (en)
KR (1) KR100509119B1 (en)
CN (1) CN1364082A (en)
AU (1) AU5713000A (en)
BR (1) BR0012431A (en)
CA (1) CA2379489A1 (en)
MX (1) MXPA02000598A (en)
WO (1) WO2001005397A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1256335A1 (en) * 2001-05-10 2002-11-13 Cognis France S.A. Use of procyanidine oligomers
KR100439627B1 (en) * 2001-06-18 2004-07-12 주식회사 엘지생활건강 Composition for preventing and treating of skin wrinkles
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
KR100441131B1 (en) * 2001-08-22 2004-07-21 애경산업(주) Cosmetic compositons for acne skin containing natural fragrant oil
KR100441565B1 (en) * 2001-09-27 2004-07-23 이형주 Extracts of buckwheat and/or buchwheat chaff with anti-inflammatory effects and food composition comprising of the same
KR20030032359A (en) * 2001-10-17 2003-04-26 주식회사 엘지생활건강 Oral pharmaceutical composition for curing periodontal disease comprising ulmus cortex extract
KR100531472B1 (en) 2002-08-09 2005-11-28 주식회사 이롬 Cosmetic composition comprising extract of Rosa multiflora with antioxdative activity and preparation method of the extract
US20060165609A1 (en) * 2004-03-26 2006-07-27 Hiroaki Inaba Periodontal ligament-protecting agent
FR2873026B1 (en) * 2004-07-13 2009-10-30 Oreal COSMETIC PROCESSING METHOD FOR PREVENTING OR DELAYING THE SIGNS OF AGING
EP1616551A1 (en) * 2004-07-13 2006-01-18 L'oreal Cosmetic treatment for preventing or delaying the signs of skin ageing
JP4941991B2 (en) * 2005-02-25 2012-05-30 国立大学法人 長崎大学 Proanthocyanidin oligomer production method
US20060194746A1 (en) * 2005-02-28 2006-08-31 Peter Rohdewald Method and composition to inhibit infections with Helicobacter pylori by intake of procyanidins from type B and C
KR100687522B1 (en) * 2005-05-28 2007-02-27 한국화학연구원 Therapeutic agent for antiinflammatory disease induced by pge2 activity containing 2,2-dimethyl-3-ester-4-alkoxy-6-alkyl amino benzopyrane derivatives as an effective ingredient
US20060293258A1 (en) * 2005-06-23 2006-12-28 Peter Rohdewald Method and composition to treat skin ulcers
JP4942953B2 (en) * 2005-06-30 2012-05-30 サントリーホールディングス株式会社 Analysis method of procyanidins
EP2265595B1 (en) * 2008-03-05 2015-07-22 Council Of Scientific & Industrial Research Novel flavonol compounds, a bioactive extract/fraction from ulmus wallichiana and its compounds for prevention for treatment of osteo-health related disorders
JP5602416B2 (en) * 2009-11-13 2014-10-08 日油株式会社 Hyaluronidase activity inhibitor
KR101438517B1 (en) * 2012-06-13 2014-09-17 경희대학교 산학협력단 Composition for prevention, improvement and treatment of acne including flavan-3-ol multimer, derivative thereof or acceptable salt thereof as an active ingredient
BR112015002030B8 (en) * 2012-08-07 2022-11-29 Indus Biotech Private Ltd USE OF A COMPOSITION COMPRISING PENTAMERIC A-TYPE PROCYANIDIN, TRIMERIC PROCYANIDINE AND TETRAMERIC PROCYANIDINE, OPTIONALLY TOGETHER WITH A PHARMACEUTICALLY ACCEPTABLE EXCIPIENT
US20140179774A1 (en) 2012-12-26 2014-06-26 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases
KR101760691B1 (en) * 2014-09-26 2017-07-24 연천군 Health functional food for preventing pancreatic adenocarcinoma
CN105998037A (en) * 2016-06-16 2016-10-12 汕头大学 Application of doxycycline to preparation of medicine for treating or preventing aging diseases
EP3501496A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Liquid delivery composition
KR102074067B1 (en) * 2018-05-02 2020-02-06 주식회사 마크로케어 Capsule comprising salvianolic acid and the use of the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219732B (en) * 1988-06-28 1990-05-24 Tecnofarmaci Spa PROCYANIDOLIC OLIGOMERIC FRACTIONS, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2672800B1 (en) * 1991-02-15 1995-03-10 Dolisos Lab NOVEL THERAPEUTIC USE OF PYCNOGENOLS FOR THE PREPARATION OF DRUGS WITH ANTI-INFLAMMATORY ACTIVITY.
WO1993024106A1 (en) * 1992-05-27 1993-12-09 L'oreal Composition comprising a proanthocyanidin oligomer encapsulated in a liposome
US5646178A (en) * 1992-10-09 1997-07-08 Jlb, Inc. Cranberry extract and biologically active compounds derived therefrom
US5554645A (en) * 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
JP3450080B2 (en) * 1995-02-01 2003-09-22 有限会社野々川商事 Health foods and pharmaceuticals containing procyanidin
WO1997023210A1 (en) * 1995-12-26 1997-07-03 Suntory Limited Antiobestic agent containing procyanidin as the active ingredient
FR2770228B1 (en) * 1997-10-27 1999-12-10 Greentech Sa PROCESS FOR OBTAINING PROANTHOCYANIDINE OLIGOMERS BY BIOFERMENTATION AND THEIR USE IN COSMETIC, DIETETIC, PHARMACEUTICAL, CHEMICAL AND FOOD COMPOSITIONS

Also Published As

Publication number Publication date
EP1196162A4 (en) 2003-06-18
CN1364082A (en) 2002-08-14
WO2001005397A8 (en) 2001-04-05
EP1196162A1 (en) 2002-04-17
CA2379489A1 (en) 2001-01-25
KR20010010154A (en) 2001-02-05
WO2001005397A1 (en) 2001-01-25
BR0012431A (en) 2002-09-24
MXPA02000598A (en) 2003-07-21
KR100509119B1 (en) 2005-08-18
JP2003504402A (en) 2003-02-04

Similar Documents

Publication Publication Date Title
AU5713000A (en) Procyanidin oligomers for inhibiting matrix metalloproteinases and medicine having effective composition of same
AU5493598A (en) N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
HUP0201214A2 (en) Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use
PL352282A1 (en) Derivatives of thiazoles and pharmaceutical compositions containing these derivatives
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
HUP0200831A3 (en) Novel pharmaceutical composition containing amoxycillin and its use
ZA987800B (en) Pharmaceutical composition of meloxicam
IL133613A0 (en) Epothilone derivatives and pharmaceutical compositions containing same
ATE263558T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING LIPASE INHIBITORS AND CHITOSAN
HUP0103874A3 (en) Use of antibiotics and pharmaceutical compositions comprising thereof
HUP0201334A3 (en) Hydrochloride of fused-heterocycle compound and pharmaceutical compositions containing the same
HUP0000965A3 (en) Pyrrolidine derivatives having phospolipase a2 inhibitory activity and pharmaceutical compositions containing the same
AU7327298A (en) Use of a pharmaceutical composition for treating and/or preventing ischemia
HUP0002037A3 (en) Hydroximic acid derivatives, use of them for producing pharmaceutical compositions suitable for inhibiting matrix metalloproteinas and pharmaceutical compositions containing the compounds
IL133223A0 (en) Novel 2-(iminomethyl) amino-phenyl derivatives preparation application as medicines and compositions containing same
HUP0102714A3 (en) Tricyclic sulfonamid derivatives as inhibitors of matrix metalloproteinases and medicaments containing the same
HUP0001438A3 (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
AU4229499A (en) Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases
AU3759100A (en) Inhibition of matrix metalloproteinases with polymers and pharmaceutical applications thereof
AU8011194A (en) Compounds, compositions and treatment of allergies and inflammation
HUP0200747A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
IL108712A0 (en) Pharmaceutical composition for the treatment of androgen-associated baldness comprising antisense oligomers
AU1730201A (en) Proteoglycans and pharmaceutical compositions comprising them
AU5065399A (en) Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
HU9802716D0 (en) Pharmaceutical composition of analgesic activity

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase